Strong Seasonality in Drug SalesThis seasonality is provided by Horizon in its Q1 report and is well known to all who invest in health care stocks.
Q1 is the weakest quarter, accounting for about 20% of annual drug sales.
Q2 is significantly stronger, Q3 larger still and Q4 is the best quarter of the year.
In other words,CXR will see sequentially larger quarters in 2016 with each being a record quarter.
With 4 new generics adding $80 million to sales in H2, there is a good chance of net earnings exceeding top line estimates